Deadly bacterial infections such as anthrax continue to pose a significant threat to human health worldwide. This disease is caused by Bacillus anthracis, which the CDC classifies as a Tier 1 biological agent due to its ability to form spores resistant to severe environmental stress conditions, including antibiotics. Identifying new antibiotics against this pathogen is therefore crucial for combatting anthrax infections. In this research, crude extracts from Pennsylvania soil were purified using various chromatography methods, resulting in natural products, which were assessed for their antimicrobial properties. After performing minimum inhibitory and bactericidal concentration assays, two compounds, AMS002 and AMS003, exhibited growth inhibitory and killing activity against B. anthracis at 0.8 mg/ml and 0.2 mg/ml, respectively. Both compounds inhibited greater than 80% of protein synthesis relative to the control samples in cell-based and in-vitro fluorescent reporter assays, suggesting that these compounds may target the bacterial protein synthesis pathway as their primary mode of action. The novelty of this discovery is vital due to the resistant nature of B. anthracis spores and their use as a potential weapon in bioterrorism. KEYWORDS: Antibiotics; Resistance; Natural Products; Chromatography; B. anthracis; Minimum Inhibitory Assay; Minimum Bactericidal Assay; Reporter Assays; Course-based Undergraduate Research Experience (CURE)
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: